Our Pipeline
Our Pipeline
Our technology platform lends itself to a wide range of applications.
We are developing a portfolio of products highlighted by a first-in-class vaccine for Respiratory Syncytial Virus (RSV), serotype-independent vaccine candidate against Streptococcus pneumoniae and Coronaviruses prophylactic approaches.
To further advance our platform and offer tangible solutions to health conditions, we welcome collaboration opportunities and various partnering options.
Our vaccines
Universal Pneumococcal Vaccine
Streptococcus pneumoniae infections cause diseases with considerable morbidity and mortality. Polysaccharide or conjugated vaccines induce serotype-specific antibodies, limiting clinical effectiveness. The emergence of new bacterial serotypes necessitates a new vaccination approach. Virometix is developing an epitope-based, serotype-independent, pneumococcal vaccine based on novel immunodominant, highly conserved antigens.
RSV Vaccine
Respiratory syncytial virus (RSV) is a prevalent, contagious respiratory pathogen, the leading cause of bronchitis and pneumonia, affecting more than 64 million people each year worldwide.
In vulnerable patients (infants and elderly) it can cause significant morbidity and mortality. After several decades of vaccine development efforts, in 2023 two recombinant vaccines were approved for adults aged 60 years and older, and one of them for women during weeks 32 through 36 of pregnancy to protect infants. With V-306 Virometix offers a differentiated approach where a neutralizing epitope on RSV-F protein is displayed on synthetic Virus-Like Particles. The vaccine was found to be safe, well-tolerated and immunogenic in a Phase I trial (NCT04519073).
Coronaviruses Vaccines
Virometix has developed vaccine candidates with broad protection against a diverse number of coronaviruses. Our epitope-focused SVLP-based candidates aim to target specific regions of the Spike protein and include protective T-cell epitopes from various viral proteins.
Cancer Vaccines
Effective antigen delivery and a strong and durable response are the basis for successful cancer vaccines. The SVLP approach, with its modular and flexible design, the inherent adjuvant properties and other immune system activators, lends itself to the development of particle-based vaccines against cancer: SVLPs displaying cancer antigens are optimally presented to the immune system and trigger cytotoxic T-cell activation in vitro and in vivo. Virometix is currently evaluating several options to provide best-in-class therapeutic solutions for cancer.
